These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. Schulman S; Lindmarker P N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063 [TBL] [Abstract][Full Text] [Related]
7. [Coagulation and bronchopulmonary cancers: from clinical aspects to biology]. Brechot JM; Conard J; Samama M Rev Mal Respir; 1992; 9(4):375-84. PubMed ID: 1324514 [TBL] [Abstract][Full Text] [Related]
8. Cancer prevention and vitamin K antagonists: an overview. Pengo V; Denas G; Jose SP; Pengo MF Thromb Res; 2010 Apr; 125 Suppl 2():S103-5. PubMed ID: 20433986 [TBL] [Abstract][Full Text] [Related]
9. Warfarin treatment in breast cancer. Zacharski LR Lancet; 1994 Jun; 343(8912):1568. PubMed ID: 7911887 [No Abstract] [Full Text] [Related]
10. A rebuttal: vitamin K antagonists and cancer survival. Zacharski LR; Henderson WG Thromb Haemost; 2002 Jul; 88(1):173-4; author reply 175. PubMed ID: 12152670 [No Abstract] [Full Text] [Related]
11. Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. Zacharski LR Onkologie; 1987 Aug; 10(4):264-70. PubMed ID: 2823201 [TBL] [Abstract][Full Text] [Related]
13. Long term anticoagulation of idiopathic venous thromboembolism: do we have the answers? Goldhaber S Clin Adv Hematol Oncol; 2003 May; 1(5):276-7. PubMed ID: 16224420 [No Abstract] [Full Text] [Related]